BÜHLMANN fCAL® ELISA Citation: Mindemark, M. & Larsson, A. Ruling out IBD: Estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin, Clinical Biochemistry. Clin Biochem. 2012 May;45(7-8):552-5. doi: 10.1016/j.clinbiochem.2011.10.015. “The estimated demand for colonoscopies was reduced by 50% to 67%. This corresponded to a cost avoidance of approximately up to €2.13 million.”
- info@buhlmannlabs.ch
- +41 61 487 12 12
Uncategorized
BÜHLMANN fCAL® ELISA Citation: Jensen, M.D., Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn’s disease affecting the small bowel and colon. Scand J Gastroenterol. 2011 Jun;46(6):694-700. doi: 10.3109/00365521.2011.560680. “The first study to show that fecal calprotectin is equally sensitive in colonic and small bowel CD.” Read More
Read more
Quantum Blue® fCAL Citation Coorevits, L, Baert F , Vanpoucke H. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method, Clinical chemistry and laboratory medicine: CCLM / FESCC. . 2013 Apr; 51(4):825-31. DOI:10.1515/cclm-2012-0386. “…we may conclude that the POCT can serve as reliable alternative to the time consuming ELISA…” Read More
Read more
Quantum Blue® fCAL Citation Lobatón, T, , López-García A, Rodríguez-Moranta F, Ruiz A, Rodríguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. Journal of Crohn's & colitis. J Crohns Colitis. 2013 Dec; 7(12):e641-51. doi: 10.1016/j.crohns.2013.05.005. “FC determined by rapid quantitative test predicts “endoscopic remission” and
Read more
Social Links